PERTH, AUSTRALIA - Mar 3, 2014 - Proteomics International, a global accredited proteomics laboratory, has signed a collaborative agreement with inVentiv Health Clinical, a leading provider of global clinical research and bioanalytical services. 

Biosimilar and biologic development begins with extensive structural and functional characterization. Proteomics International provides structural characterization and QC testing of proposed and referenced products with an advanced suite of scientific instrumentation. These services complement inVentiv Health's array of bioanalytical capabilities from clinical development through commercialization in support of biosimilar development.

The Proteomics International agreement with inVentiv Clinical offers developers the ability to seamlessly transition from characterization to clinical trials thereby streamlining the process and providing a competitive advantage in the race to market.

"We welcome the partnership with inVentiv as it represents a significant opportunity for us in furthering expansion into bio-generic markets", said Dr. Richard Lipscombe, Managing Director of Proteomics International. "This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment."

"The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients", said Dr. George Scott, Vice President, Bioanalytical Services for inVentiv Clinical. "Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct, and registration to commercialization. "

About Proteomics International

Proteomics International is privately owned, founded in 2001, with strong presence in the Asian markets and a sustainable business model that operates in three synergistic business units: Diagnostics (biomarker discovery), Therapeutics (drug discovery of peptide medicines) and Analytics (Biosimilars CRO). The Company is commercializing a panel of biomarkers for diabetic kidney disease and has self funded $5 million to develop a proven protein biomarker discovery platform that could be used for other diseases (humans, veterinary and agriculture). The kidney disease biomarkers are being cross-validated in highly curated diagnostic and prognostic clinical studies with immunoassays and mass spectrometry to develop a diagnostic kit for the RUO, LDT, IVD, POC and CDx markets. The Company has also developed a proprietary peptide drug discovery process that analyzed proteins from venom to identify several potential lead compounds (analgesics and antimicrobials).  The success rates for this process are 100 times greater than the industry standard hit-rate for small molecule primary screens.

About inVentiv Health Clinical

About inVentiv Health Clinical inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 6,500 passionate employees supporting clients in more than 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. www.inventivhealthclinical.com